Psma binding ligand-linker conjugates and methods for using

Abstract

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

1 .- 29 . (canceled) 
     
     
         30 . A compound of the formula:
   B-L-IA   or a pharmaceutically acceptable salt thereof, wherein:   B is of the formula   
       
         
           
           
               
               
           
         
         wherein * represents the point of attachment to L; 
         L is a divalent linker of 7 to 100 atoms in length, the divalent linker comprising at least one polyoxyalkylene portion, a divalent amino alkylene carbonyl group, and at least one divalent arylene group; 
         L does not comprise an arylalkyl side chain; and 
         IA is an optical imaging agent selected from the group consisting of fluorescein, BODIPY F1, BODIPY 505, tetramethylrhodamine, AlexaFluor 488, AlexaFluor 647, DyLight 680, DyLight 800, IR800CW, indocyanine green, Oregon Green 488, Oregon Green 514, Texas Red, and phycoerythrin. 
       
     
     
         31 . The compound of  claim 30 , wherein the at least one divalent arylene group is a divalent alkylarylene group.